Navigation Links
Omeros Corporation Files Registration Statement for Proposed Initial Public Offering
Date:1/9/2008

SEATTLE, Jan. 9 /PRNewswire/ -- Omeros Corporation announced today that it has filed a registration statement with the Securities and Exchange Commission relating to the proposed initial public offering of shares of its common stock. All shares of the common stock to be sold in the offering will be offered by Omeros. Deutsche Bank Securities Inc. will be acting as the sole book-running manager. Pacific Growth Equities, LLC will be acting as the co- lead manager, and Leerink Swan LLC and Needham & Company, LLC will be acting as co-managers. The offering will be made only by means of a prospectus. When available, copies of the preliminary prospectus may be obtained from Deutsche Bank Securities Inc. by mail, Attn: Prospectus Department, 100 Plaza One, Floor 2, Jersey City, NJ 07311, by telephone at (800)-503-4611 or by email: prospectusrequest@list.db.com.

A registration statement relating to these securities has been filed with the Securities and Exchange Commission but has not yet become effective. These securities may not be sold nor may offers to buy be accepted prior to the time that the registration statement becomes effective. This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Omeros Corporation

Omeros Corporation is a clinical-stage biopharmaceutical company committed to discovering, developing and commercializing products focused on inflammation and disorders of the central nervous system. Omeros' most clinically advanced product candidates are derived from its proprietary PharmacoSurgery(TM) platform designed to improve clinical outcomes of patients undergoing arthroscopic, ophthalmological, urol
'/>"/>

Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Genelex Corporation Defends Consumers Right to Obtain DNA Information:
2. Pharmos Corporation Completes Initial Closing of Private Placement
3. Pharmos Corporation Announces Board and Management Changes
4. Environmental Tectonics Corporation Announces Sale of Monoplace Hyperbaric Chambers
5. CuraGen Corporation Announces Appointment of Sean Cassidy as CFO
6. LifeCell Corporation Schedules 2008 Financial Guidance Release and Conference Call; January 7, 2008 at 10:00 A.M. Eastern
7. Pharmos Corporation Announces President & COO Alan L. Rubino to Leave Company
8. Shire Expands its Gastrointestinal Portfolio Through In-Licensing Celiac Disease Phase 2 Product From Alba Therapeutics Corporation
9. Alba Therapeutics Corporation and Shire plc Enter Into $325 Million ex-US, ex-Japan Licensing Agreement to Develop and Commercialize AT-1001
10. FMC Corporation and Pronova BioPharma Announce Agreement To Develop New Alginate-Based Capsule Products
11. Genaera Corporation to Participate in Diabetes and Obesity Panel at RBC Capital Markets Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2015)... VANCOUVER , Aug. 28, 2015 /PRNewswire/ - ... clinical stage regenerative medicine company focused on the ... results for the quarter ended June 30, 2015, ... statements and management report are available at ... www.replicel.com . "RepliCel expects to ...
(Date:8/28/2015)... ... August 28, 2015 , ... Since the initial launch of FireflySci Inc. (FFS) in early 2015, ... customer service. Images such as the Fonz in a lab coat and Large Marge ... the humdrum spectroscopy field. , FireflySci is proud to be the only cuvette ...
(Date:8/27/2015)... (PRWEB) , ... August 27, 2015 , ... Capital ... solve complex business problems, is pleased to announce their ranking as one of the ... ranking of the fastest-growing private companies across the nation. , “It is truly an ...
(Date:8/27/2015)... 27, 2015 /PRNewswire/ - Portage Biotech Inc. ("Portage") ... Biohaven Pharmaceutical Holding Company Limited (Biohaven), announced today ... study of BHV-0223, a glutamate modulating agent. Biohaven ... and recently obtained clearance from the U.S. Food ... testing. Portage holds 54% equity interest in Biohaven, ...
Breaking Biology Technology:RepliCel Reports Second Quarter 2015 Financial Results 2RepliCel Reports Second Quarter 2015 Financial Results 3RepliCel Reports Second Quarter 2015 Financial Results 4RepliCel Reports Second Quarter 2015 Financial Results 5Cuvette Manufacturer FireflySci Launches Back to School Deals with Complimentary Shipping On All Orders 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 2Capital Edge Consulting Makes Inc. 5000 List of America’s Fastest-Growing Private Companies 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 2Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 3Portage's Biohaven doses first human subject in Phase 1 trial with lead drug candidate BHV-0223 4
... , ATLANTA, Sept. 21 GeoVax ... Atlanta-based, biopharmaceutical company developing human vaccines for diseases caused by ... that it has requested a pre-Investigational New Drug (IND) meeting ... a proposed IND for GeoVax,s therapeutic vaccine as a treatment ...
... , RANCHO CORDOVA, Calif., Sept. 21 ThermoGenesis Corp. ... for processing and storing adult stem cells, said today it had ... become non-compliant with the Nasdaq Capital Markets, minimum bid pricing requirement ... past 30 days had failed to meet the minimum bid of ...
... , CAMBRIDGE, Mass., Sept. 21 Merrimack ... the company as Senior Vice President, Development. Dr. Niyikiza comes ... and Medicine Development Leader for oncology. Dr. Niyikiza has ... over 18 years in the pharmaceutical industry in which he ...
Cached Biology Technology:GeoVax Labs Requests pre-IND Meeting With FDA 2GeoVax Labs Requests pre-IND Meeting With FDA 3ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule 2ThermoGenesis Receives Notice Related to Nasdaq Minimum Closing Bid Price Rule 3Merrimack Pharmaceuticals Names Clet Niyikiza, Ph.D. Senior Vice President, Development 2
(Date:8/12/2015)... YORK , Aug. 12, 2015  New ... hackers can attack Android phones to steal users, ... the increasing availability of fingerprint scanners on mobile ... utmost concern. To secure biometrics on mobile devices, ... to augment these convenient authentication systems with strong ...
(Date:8/10/2015)... and TELTOW, Germany , ... Instruments (SMI), a world leader in Eye Tracking ... completion of its OEM Eye Tracking Platform for integration ... Tracking Platform contains reference designs for seamless integration of ... systems, virtual reality HMDs and augmented reality smart glasses. ...
(Date:8/6/2015)... Germany , August 6, 2015 /PRNewswire/ ... SensoMotoric Instruments (SMI) shows the world,s first ... based on Epson,s Moverio BT-200 see-through head mounted display ... new solution, unprecedented quality and efficiency is brought to ... displays. For the first time, professionals and researchers can ...
Breaking Biology News(10 mins):HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 2HYPR Corp. Addresses Android Vulnerability That Exposes Ecosystem-wide Biometric Security Challenges 3SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 2SMI Shows First Eye Tracking Upgrade for Augmented Reality Glasses 3
... 12-hour, dual-stage surgery known to be performed at only ... University of Alabama at Birmingham on Tuesday returned a ... his pancreas to eliminate constant, severe pain from chronic ... City, Fla., remained anesthetized in the operating room at ...
... new way to sabotage DNA's ability to reproduce, a ... new anti-cancer drugs and therapies. , The method could ... than directing chemotherapeutic medication or radiation to tumors through ... in the university's Zanvyl Krieger School of Arts and ...
... that does not require oxygen, Penn State environmental engineers ... the first process that enables bacteria to coax four ... can be generated typically by fermentation alone. , Dr. ... an inventor of the MFC, says, "This MFC process ...
Cached Biology News:Rare surgery performed to remove pancreas, prevent diabetes 2Microbial fuel cell: High yield hydrogen source and wastewater cleaner 2
... grow, the need for greater detection of ... especially when discerning very similar or closely ... Microscope System gives you a level of ... in conventional confocal systems, with detectors for ...
... Science LAS-3000 imaging system combines new ... user interface, providing significantly improved system ... modularities. The LAS-3000 provides significantly improved ... of applications including: fluorescence, chemifluorescence, chemiluminescence, ...
The LAS-3000 imaging system combines new CCD camera technology with a simplified user interface to provide significantly improved system sensitivity with a wide range of modularities. This system is...
Capture faint-light images without losing sensitivity or resolution. With its brand new hardware and interface design, the LAS-1000plus turns sample imaging into a simple process....
Biology Products: